OLYMPUSby New Odyssey
Menu
SEC registrant · CIK 0001420565

Rein Therapeutics, Inc. (RNTX)

Rein Therapeutics, Inc. (CIK 0001420565, ticker RNTX, EIN 13-4196017) reported revenue of $0 for FY2025 (2025-01-01 to 2025-12-31) and net income of -$49.87 million (-$49,871,000) for FY2025 (2025-01-01 to 2025-12-31), as filed in its 10-K filed 2026-03-26 (accession 0001193125-26-126385).

Figures are as filed with the SEC in XBRL, in whole US dollars unless stated, for the company's own fiscal years (fiscal year ends December 31).

Data as of Oct 21, 2026 (Olympus publication) · Markdown version

  • Values are as filed by the company in its 10-K and 10-Q XBRL data. When a later filing restates a value, the latest filed value is shown and the first reported value is noted.

Identifiers

As published in the company's EDGAR submissions record.

IdentifierValue
CIK0001420565
TickersRNTX (Nasdaq)
EIN13-4196017
SIC industry code2834 Pharmaceutical Preparations
Fiscal year endDecember 31
Filer categoryNon-accelerated filer<br>Smaller reporting company
Entity typeoperating
Olympus entity IDorg_3ndz8x7m9tdg2kmjj9nw1r3jwz
  • The EIN is the one the filer gave to EDGAR. The SEC does not verify it; Olympus checks only that it has nine digits and a prefix the IRS assigns.

Latest annual financial metrics

The latest annual value of each standardised metric, with the filing it was taken from.

MetricValueFiscal periodPeriodFormFiledAccession numberXBRL concept
Revenue$0FY20252025-01-01 to 2025-12-3110-K2026-03-260001193125-26-126385RevenueFromContractWithCustomerExcludingAssessedTax
Net income-$49,871,000FY20252025-01-01 to 2025-12-3110-K2026-03-260001193125-26-126385NetIncomeLoss
Total assets$24,158,000FY2025as of 2025-12-3110-K2026-03-260001193125-26-126385Assets
Total liabilities$7,240,000FY2025as of 2025-12-3110-K2026-03-260001193125-26-126385Liabilities
Stockholders' equity$16,918,000FY2025as of 2025-12-3110-K2026-03-260001193125-26-126385StockholdersEquity
Operating cash flow-$19,361,000FY20252025-01-01 to 2025-12-3110-K2026-03-260001193125-26-126385NetCashProvidedByUsedInOperatingActivities
Diluted earnings per share-$1.96 per shareFY20252025-01-01 to 2025-12-3110-K2026-03-260001193125-26-126385EarningsPerShareDiluted
Shares outstanding28,039,032 sharesFY2025as of 2026-03-2410-K2026-03-260001193125-26-126385EntityCommonStockSharesOutstanding
  • Accession numbers link to the filing's index on SEC EDGAR.

Revenue and net income history

Every annual revenue and net income value served for fiscal years 2016-2025, newest first, each with its filing.

MetricFiscal periodPeriodValueFormFiledAccession number
RevenueFY20252025-01-01 to 2025-12-31$010-K2026-03-260001193125-26-126385
RevenueFY20242024-01-01 to 2024-12-31$010-K2026-03-260001193125-26-126385
RevenueFY20232023-01-01 to 2023-12-31$010-K2025-04-070000950170-25-051566
RevenueFY20222022-01-01 to 2022-12-31$010-K2024-04-150000950170-24-044508
RevenueFY20212021-01-01 to 2021-12-31$010-K2023-03-200000950170-23-008767
RevenueFY20202020-01-01 to 2020-12-31$010-K2022-03-280000950170-22-004774
RevenueFY20192019-01-01 to 2019-12-31$010-K2021-03-240001564590-21-015115
RevenueFY20182018-01-01 to 2018-12-31$010-K2020-03-300001564590-20-014155
RevenueFY20172017-01-01 to 2017-12-31$010-K2018-04-020001564590-18-007403
Net incomeFY20252025-01-01 to 2025-12-31-$49,871,00010-K2026-03-260001193125-26-126385
Net incomeFY20242024-01-01 to 2024-12-31-$62,883,00010-K2026-03-260001193125-26-126385
Net incomeFY20232023-01-01 to 2023-12-31-$15,732,00010-K2025-04-070000950170-25-051566
Net incomeFY20222022-01-01 to 2022-12-31-$27,329,00010-K2024-04-150000950170-24-044508
Net incomeFY20212021-01-01 to 2021-12-31-$26,164,00010-K2023-03-200000950170-23-008767
Net incomeFY20202020-01-01 to 2020-12-31-$27,329,00010-K2023-03-200000950170-23-008767
Net incomeFY20192019-01-01 to 2019-12-31-$29,369,00010-K2021-03-240001564590-21-015115
Net incomeFY20182018-01-01 to 2018-12-31-$31,547,00010-K2020-03-300001564590-20-014155
Net incomeFY20172017-01-01 to 2017-12-31-$22,604,00010-K2019-03-290001564590-19-010007
  • Net income for FY2020 was restated: first reported as -$21,157,000 (accession 0001564590-21-015115, filed 2021-03-24).

Recent 10-K and 10-Q filings

The 12 most recent 10-K, 10-Q and amendment filings in EDGAR, newest first.

FormFiledPeriod of reportAccession numberDocument
10-Q2026-08-142026-06-300001193125-26-350270rntx-20260630.htm
10-Q2026-05-152026-03-310001193125-26-225352rntx-20260331.htm
10-K/A2026-04-272025-12-310001193125-26-178787rntx-20251231.htm
10-K2026-03-262025-12-310001193125-26-126385rntx-20251231.htm
10-Q2025-11-142025-09-300001193125-25-281622rntx-20250930.htm
10-Q2025-08-142025-06-300000950170-25-108836rntx-20250630.htm
10-Q2025-05-152025-03-310000950170-25-072607rntx-20250331.htm
10-K/A2025-04-302024-12-310001193125-25-107666d937270d10ka.htm
10-K2025-04-072024-12-310000950170-25-051566rntx-20241231.htm
10-Q2024-11-142024-09-300000950170-24-127019alrn-20240930.htm
10-Q2024-08-142024-06-300000950170-24-097199alrn-20240630.htm
10-Q2024-05-152024-03-310000950170-24-060583alrn-20240331.htm

Identifier registry

The company's identifiers in the Olympus identifier registry, each with how it was linked and its source.

SchemeValueHow linkedSourcePublished
SEC Central Index Key (CIK) · OLY-US-SEC-CIK0001420565published by the sourcedata.sec.gov/submissions/CIK0001420565.json2026-10-21
Employer Identification Number (EIN) · US-EIN13-4196017published by the sourcedata.sec.gov/submissions/CIK0001420565.json2026-10-21

Former names

NameFromTo
Aileron Therapeutics, Inc.2024-04-012024-12-09
AILERON THERAPEUTICS INC2007-12-032024-03-29

Sources

  • EDGAR submissions (nightly bulk archive) (company profile and filings) — U.S. Securities and Exchange Commission. EDGAR snapshot sha256:f7d2a4f18cb91aae, source date 2026-10-20. https://data.sec.gov/submissions/CIK0001420565.json
  • EDGAR XBRL company facts (nightly bulk archive) (financial metrics) — U.S. Securities and Exchange Commission. EDGAR snapshot sha256:01e4045aa34d7224, source date 2026-10-20. https://data.sec.gov/api/xbrl/companyfacts/CIK0001420565.json
  • Published by Olympus on Oct 21, 2026.
  • Source data: U.S. Securities and Exchange Commission (EDGAR). Values are as filed by the registrant; Olympus does not audit or adjust them.
  • Olympus is not affiliated with or endorsed by the U.S. Securities and Exchange Commission.

Get this data from the API

The same figures, with provenance on every value, from the API (free API key, reference) or from an AI agent through the Olympus MCP server.

curl
curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0001420565" -H "X-API-Key: $OLYMPUS_API_KEY"

curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0001420565/financials" -H "X-API-Key: $OLYMPUS_API_KEY"

curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0001420565/filings?limit=12" -H "X-API-Key: $OLYMPUS_API_KEY"
MCP tool call
get_sec_company_financials {"cik":"1420565"}

On SEC EDGAR

About this data